Trasplante de Células Madre para pacientes con Mieloma Múltiple


Published on

Trasplantes de Células Madre a un costo bajo y alta calidad. Medicenter es una clínica en Guatemala (al sur de Mexico) especializada en el trasplante de células madre. Si usted vive fuera de Guatemala podemos organizar su viaje. Si vive en Estados Unidos podemos ofrecerle financiamiento. Para mayor informacion:

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • INTRODUCTION: The Summary Slides are an annual report on data submitted to the CIBMTR. This year, the slides are being posted online at for easy accessibility, rather than published as part of the CIBMTR Newsletter. This change allowed us to combine parts I and II into one comprehensive set, updating the content in a format similar to previous years. Slides 1 to 25 exhibit data on frequency of transplants according to age, donor and transplant type, graft source and disease, and early outcomes such as 100-day mortality by disease and transplant type. Slides 26 to 49 include overall survival outcomes according to disease, disease status, donor type, year of transplant and conditioning regimen intensity. Comparisons across survival curves are univariate and do not adjust for all potentially important factors; consequently, results should be interpreted cautiously. Acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) are classified as early disease (first complete remission [CR1] or first chronic phase [CP1]), intermediate (second or subsequent CR or CP or accelerated phase [AP]), or advanced (primary induction failure, active disease, or blastic phase) disease. Myelodysplastic syndrome (MDS) is divided into early (refractory anemia [RA] or refractory anemia with ringed sideroblasts [RARS]), or advanced (refractory anemia with excess of blasts [RAEB] or chronic myelomonocytic leukemia [CMML]) disease. Lymphoma is classified according to sensitivity to prior chemotherapy (chemosensitive or chemoresistant). The classification of conditioning regimen intensity is based on the agents, doses and schedules used. Several classification systems are available, and for this report we used a composite classification. Cases defined as reduced-intensity by the transplant center were classified as such. Cases without such information and with available data on chemotherapy agents, radiation and doses, were classified according to the CIBMTR operational definition of conditioning regimen intensity:   Myeloablative conditioning regimen : regimens with total body irradiation doses of ≥500 cGY, single fractionated doses of ≥800 cGY, busulfan doses of >9mg/kg, or melphalan doses of >150 mg/m 2 given as single agents or in combination with other drugs. Reduced-intensity conditioning regimen : regimens with lower doses of total body irradiation, fractionated radiation therapy, busulfan, and melphalan than those used to define a myeloablative conditioning regimen (above). Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2010. Available at :
  • Slide 4: Estimated annual numbers of transplants in the U.S. were compiled according to the number registered with CIBMTR. Estimates of how closely the numbers reported are representative of actual transplant activity vary according to the type of transplant and number of centers reporting data per year. Prior to 2007, all except unrelated donor allogeneic transplant facilitated by the NMDP were reported voluntarily. It was estimated that the CIBMTR captured 90% of all unrelalted donor transplants performed in North America, 55 to 65% of related donor allogeneic transplants and 45 to 55% of autologous transplants. These estimates were extrapolated from other databases that capture transplant center activity, accreditation or hospital discharges. After 2007, the Stem Cell Transplant Outcomes Database (SCTOD) was initiated which changed reporting requirements and data capture to an electronic format. The SCTOD requires that all allogeneic transplants performed in the US be registered with CIBMTR. Data reporting of autologous transplants remains voluntary and the numbers in the CIBMTR database are estimated to be 55%. US numbers of allogeneic transplants in the CIBMTR are representative of the actual transplant activity. The number of autologous transplants in the U.S. has steadily increased since 2000. Allogeneic transplants from unrelated donors surpassed the number of allogeneic transplants from related donors after 2007. The major contributing factors to this trend are the growth of unrelated donor databases and improvements in unrelated donor transplant.
  • Slide 6 : Mobilized peripheral blood progenitor cells are the most common graft source used in autologous transplants, accounting for 91% and 98% in children and adults, respectively, for the period from 2004 to 2008. The practice of combining bone marrow with peripheral blood progenitor cells in patients unable to mobilize optimal cell doses has decreased in both adults and children (<1%). Better mobilization regimens and patient selection may account for the rarity of this practice of late.
  • Slide 3: Estimates of annual numbers of hematopoietic stem cell transplants worldwide, extrapolated from data compiled by the CIBMTR, European Blood and Marrow Transplant Group (EBMT), published reports from the Worldwide Network for Blood and Marrow Transplantation (WBMT) and the Asia Pacific Blood and Marrow Transplant Group (APBMT). Autologous transplant trends demonstrate changes in practice over time, with transplants for breast cancers in the early 1990s accounting for the majority of activity, and after 1999, lymphoproliferative disorders accounting for most of these transplants. The annual numbers of autologous transplants worldwide have continued to increase as a result of wider utilization of this treatment and its extension to recipients older than 60 years. The numbers of allogeneic transplants have increased steadily over the past three decades. In the early 2000s, the increase in annual transplant numbers was slower than previous years, which is likely a result of a decrease in transplants performed for treating chronic myeloid leukemia (CML). This trend was mostly observed in countries classified by the World Bank as having high or intermediate-high gross national income. Subsequent trends in allogeneic transplant have shown a more rapid increase in annual numbers, which can be explained by higher number of unrelated donor transplants, older recipients being transplanted using reduced-intensity conditioning regimens, and the expanding utilization of umbilical cord blood.
  • Slide 7 : The number of autologous and allogeneic transplants for treatment of malignant diseases in older patients is increasing. Thirty-four percent of autologous transplant recipients and 12% of allogeneic transplant recipients in 2004-2008 were older than 60. The majority of autologous transplant recipients (65%) and 34% of allogeneic transplant recipient were older than 50 in this later period.
  • Slide 9 : The most common indication for transplant was lymphoproliferative disorders (plasma cell disorders and lymphomas) in 2008, accounting for 60% of all transplants. Also in 2008, 52% of allogeneic transplants were performed for treatment of acute leukemias, and 45% of autologous transplants were performed for treatment of multiple myeloma.
  • Slide 17 : The 100-day mortality rate is often cited to reflect the toxicity of the transplantation process. Autologous transplants have a much lower rate of 100-day mortality than allogeneic transplants. The primary disease and the disease status at the time of transplantation significantly affect early post-transplant mortality.
  • Slides 18-20 : The effect of disease stage is even more apparent for allogeneic transplants. Patients receiving an HLA-identical sibling transplant for AML in remission have a 100-day mortality rate of 7 to 9%, compared to 22% for patients with active leukemia at the time of transplantation. Early mortality after an unrelated donor transplant is higher than after an HLA-identical sibling transplantation, but the rate also depends on the disease and disease stage. The causes of death in the first 100 days post-transplant mainly relate to the primary disease, graft-versus-host disease, infection and end-organ damage. After an autologous transplant, primary disease is the most commonly reported cause of death. Among allogeneic transplant recipients, unrelated donor transplants have fewer deaths related to the primary disease, however organ failure and infections are higher after unrelated donor transplants.
  • Slide 49: Multiple myeloma (MM) is the most common indication for an autologous transplant. Among 22,254 patients who received a single autologous transplant for MM between 1998 and 2008, the 3-year probability of survival was 68% ± 1%. Allogeneic transplantation for MM is reserved for patients with high risk disease, and the majority are performed after an autologous transplant with reduced-intensity or nonmyeloablative conditioning regimens. Among the 1,021 patients who received an allogeneic transplant for MM from 1998 to 2008, the 3-year probabilities of survival were 47% ± 2% for the 878 recipients of HLA-matched sibling donor transplants and 28% ± 4% for the 143 recipients of unrelated donor transplants.
  • Trasplante de Células Madre para pacientes con Mieloma Múltiple

    1. 2. Mieloma Múltiple Información para pacientes con Mieloma Múltiple Dr. Byron Sánchez/MEDICENTER Septiembre 2010
    2. 9. Nuestras Afiliaciones <ul><li>Asociación Guatemalteca de Medicina Interna </li></ul><ul><li>Asociación de Hemato-Oncología de Guatemala </li></ul><ul><li>Comisión de Turismo Médico y Bienestar de Agexport </li></ul><ul><li>International Cellular Medicine Society </li></ul><ul><li>International Society for Cellular Therapy </li></ul>
    3. 11. <ul><li>Basic Concepts of Transplantation </li></ul><ul><li>HSC’s possess unique characteristics that </li></ul><ul><li>make transplants possible. </li></ul><ul><li>their ability to regenerate in the marrow </li></ul><ul><li>their ability to find their way back to the bone </li></ul><ul><li>marrow following intravenous infusion. </li></ul><ul><li>their ability to be cryopreserved with little or </li></ul><ul><li>no damage. </li></ul>
    4. 12. Sources
    5. 15. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt
    6. 16. Transplant activity in the U.S. 1980-2009 Transplants '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 Autologous Related Donor Unrelated Donor SUM10_4.ppt Slide 4 10,000 8,000 18,000 12,000 6,000 4,000 2,000 0 16,000 14,000
    7. 17. Autologous stem cell sources, by recipient age 1999-2008 Transplants, % SUM10_8.ppt Slide 6 Age  20 yrs Age  20 yrs 1999-2003 2004-2008 1999-2003 2004-2008 80 100 60 40 20 0 Bone Marrow (BM) Peripheral Blood (PB) BM + PB
    8. 18. Transplant activity worldwide 1980-2009 Transplants SUM10_3.ppt Slide 3 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 20,000 Autologous Allogeneic 25,000 35,000 30,000 15,000 10,000 5,000 0
    9. 19. Trends in transplantation, by transplant type and recipient age * 1999-2008 Transplants, % SUM10_9.ppt Slide 7 Allogeneic Transplants Autologous Transplants 1999-2003 2004-2008 1999-2003 2004-2008 * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma 80 100 60 40 20 0  20 yrs 21-40 yrs 41-50 yrs 51-60 yrs  60 yrs
    10. 20. Indications for hematopoietic stem cell transplant in North America 2008 SUM10_11.ppt Slide 9 Number of Transplants Multiple Myeloma NHL AML HD ALL MDS/MPD Aplastic Anemia CML Other Leuk Other Cancer Non- Malig Disease Allogeneic (Total N=6,672) Autologous (Total N=10,302) 3,000 5,500 2,000 1,500 500 0 1,000 2,500 3,500 4,000 4,500 5,000
    11. 21. MIELOMA MULTIPLE <ul><li>Tx Autologo es el tratamiento de preferencia todo paciente con mieloma debe de ser evaluado como candidato a transplante </li></ul><ul><li>Tx Allogenico es todavia investigacional </li></ul>
    12. 22. MIELOMA MULTIPLE <ul><li>Mieloma Sintomatico </li></ul><ul><li>Edad </li></ul><ul><ul><li>USA < 77 Europa < 65 </li></ul></ul><ul><li>Bililrubina </li></ul><ul><ul><li><2.0 </li></ul></ul><ul><li>Funcion Renal </li></ul><ul><ul><li>< 2.5 </li></ul></ul><ul><li>PS ECOG </li></ul><ul><ul><li>< 3 </li></ul></ul><ul><li>Funcion Cardiaca </li></ul><ul><ul><li>< clase III </li></ul></ul>
    14. 24. MIELOMA MULTIPLE IFM 90 TX AUTO QUIMIO RR 81% 57% CR 22% 5% EFS 7a. 16% 8% OS 57% 44%
    15. 25. 100-day mortality after autologous transplantation 2007-2008 SUM10_19.ppt Slide 17 Mortality, % 12 15 9 6 3 0 Acute Leukemia Non-Hodgkin Lymphoma Hodgkin Disease Multiple Myeloma Early Disease Intermediate/Advance Disease Sensitive Resistant Other
    16. 26. Causes of death after transplantations done in 2003-2008 SUM10_22.ppt Slide 20 Infection (17%) Other Cause (19%) Organ Failure (12%) Primary Disease (35%) IPn * (5%) GVHD (12%) Infection (14%) Other (22%) GVHD (10%) Primary Disease (43%) IPn * (3%) Organ Failure (8%) Infection (5%) Other Cause (17%) Organ Failure (4%) IPn * (1%) Primary Disease (73%) *IPn = Idiopathic pneumonia syndrome Autologous Unrelated donor HLA-identical sibling
    17. 27. Probability of survival after transplant for multiple myeloma, by donor type 1998-2008 Years 0 2 6 1 3 4 5 Probability of Survival, % HLA-matched sibling, Allo (N=878) autologous transplant (N=22,254) Unrelated, Allo (N=143) P < 0.0001 SUM10_56.ppt Slide 49 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90
    18. 28. MIELOMA MULTIPLE <ul><li>PREGUNTAS ??????? </li></ul><ul><ul><li>TRATAMIENTO A PACIENTES DE ALTO RIESGO </li></ul></ul><ul><ul><ul><li>CITOGENETICA Y FISH (CHROMOSOMAS 13 O 14) </li></ul></ul></ul><ul><ul><li>TRATAMIENTO CON NUEVAS DROGAS </li></ul></ul><ul><ul><ul><li>BORTEZOMIB THALIDOMIDA LENOLIMIDA </li></ul></ul></ul><ul><ul><li>TRATAMIENTO EN BASE A EDAD </li></ul></ul><ul><ul><ul><li>TERAPIAS MODIFICADAS </li></ul></ul></ul>
    19. 30. Recomendable!
    20. 31. PASO I Terapia de Inducción 4-6meses
    21. 32. Paso II Documentar Respuesta
    22. 33. Paso III Movilización de Stem Cells
    23. 34. Paso IV Recolección por Aféresis
    24. 35. Paso V Separación y Criopreservación
    25. 36. Paso VI Hospitalización y Quimioterapia de acondicionamiento 48 horas
    26. 37. Paso VII Reinfusión de Stem Cells 48 horas posterior a Quimio
    27. 38. Efectos Adversos <ul><li>Mielosupresión transitoria (promedio 7 días) </li></ul><ul><li>Fiebre en el 40% de los pacientes </li></ul><ul><li>Mucositis en el 30% de los pacientes </li></ul><ul><li>Alopecia transitoria </li></ul><ul><li>La infusión de las células puede asociarse a : náusea, vómitos, dolor de cabeza, escalofríos y fiebre. Todos leves y transitorios </li></ul>
    28. 39. OPCIONES PARA HOSPITALIZACION <ul><li>Hospitales tipo AAA </li></ul><ul><li>Ubicados en la Ciudad de Guatemala </li></ul><ul><li>A 10 mns del Aeropuerto y de los principales hoteles de la Zona Viva de la Ciudad de Guatemala </li></ul><ul><li>Servicios de emergencia, encamamiento, laboratorio clínico y diagnóstico por imágenes </li></ul><ul><li>Intensivo y Banco de Sangre </li></ul>
    29. 41. Búscanos y Contáctanos <ul><li>Todas nuestras páginas web: /medicenter </li></ul><ul><li>Página web de mieloma múltiple: http :// stem - cell - multiple - / </li></ul><ul><li>Turismo medico: </li></ul><ul><li>Facebook: http :// /Medicenter </li></ul><ul><li>Twitter: http :// / stem_cell_trans </li></ul>
    30. 42. [email_address]